Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression
批准号:
8109826
负责人:
Markus H. Frank
金额:
$33.76万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-24 至 2013-07-31
关键词:
AdultBindingBreslow ThicknessCell LineCellsClinicalDiagnosisDisease ProgressionDisseminated Malignant NeoplasmDrug resistanceEarly DiagnosisEmbryoExcisionExperimental NeoplasmsFailureFamilyGene ExpressionGenesGrowthHumanHumpback DolphinsIn VitroInfiltrationKnowledgeLaboratoriesMalignant NeoplasmsMediator of activation proteinMelanoma CellMinorityModelingMolecularMolecular ProfilingMulti-Drug ResistanceNeoplasm MetastasisOperative Surgical ProceduresPathway interactionsPatientsPatternPopulationProcessRadial Growth PhaseResistanceRoleStem cellsSurvival RateSystemic TherapyTherapeuticTreatment ProtocolsTumor Stem CellsUndifferentiatedVisceralWorkXenograft procedurebasecancer stem cellcancer therapychemotherapyconventional therapyimprovedlifetime risklymph nodesmelanomamembermimicrymortalitynovelnovel strategiesnovel therapeuticsoutcome forecastself-renewaltherapy resistanttumortumor growthtumor initiationtumor progressiontumorigenesisvasculogenesis
中文摘要
描述(申请人提供):人类黑色素瘤是一种高度侵袭性和抗药性的癌症,一旦扩散就对系统治疗产生抗药性。这种恶性肿瘤中具有胚胎样可塑性的未分化亚群的发现表明存在黑色素瘤干细胞。最近,我们的实验室已经鉴定出黑色素瘤干细胞,其特征是表达化疗耐药介质ABCBS,它与黑色素瘤的进展有关,并可作为实验性肿瘤异种移植模型的治疗靶点。黑色素瘤干细胞触发肿瘤发生和促进肿瘤进展的分子和细胞机制目前尚不清楚。血管生成和转移是公认的对肿瘤生长和肿瘤进展至关重要的现象。尽管对所涉及的分子途径有重要的了解,但到目前为止还没有证明癌症干细胞与这些过程的具体关系。我们假设,能够自我更新和分化的黑色素瘤干细胞可能与参与肿瘤血管生成和转移的癌症亚群重合,因此,针对这一细胞群体和相关分子途径的特异性靶向可能为根除目前对常规治疗耐药的癌症提供新的策略。这项建议的具体目的如下:(1)研究ABCBS+黑色素瘤干细胞与肿瘤血管生成的关系,并确定所涉及的分子机制;(2)确定ABCBS+黑色素瘤干细胞在转移性肿瘤进展中的作用;(3)开发新的黑色素瘤干细胞靶向治疗。因此,该提案与旨在开发基于选择性靶向癌症干细胞中的重要分子通路的癌症治疗的新治疗策略的努力高度相关。
英文摘要
DESCRIPTION (provided by applicant): Human melanoma is a highly aggressive and drug resistant cancer and resistant to systemic therapy once disseminated. Findings of undifferentiated subpopulations with embryonic-like plasticity within this malignancy have pointed to the presence of melanoma stem cells. Recently our laboratory has identified melanoma stem cells characterized by expression of the chemoresistance mediator ABCBS, which are responsible for melanoma progression and can be therapeutically targeted in experimental tumor xenotransplantation models. The molecular and cellular mechanisms by which melanoma stem cells trigger tumorigenesis and promote neoplastic progression are currently unknown. Vasculogenesis and metastasis are phenomena recognized to be critical for tumor growth and neoplastic progression. Despite the significant knowledge about the molecular pathways involved, a specific relationship of cancer stem cells to these processes has not been demonstrated to date. We hypothesize that melanoma stem cells capable of self-renewal and differentiation, which are responsible for tumor growth, may coincide with cancer subpopulations critically involved in tumor vasculogenesis and metastasis and that specific targeting of this cell population and of related molecular pathways could thus provide for novel strategies to eradicate cancers currently resistant to conventional therapy. The specific aims of this proposal are the following: (1) Investigate the relationship between ABCBS+ melanoma stem cells and tumor vasculogenesis and define the molecular mechanisms involved; (2) Define the role of ABCBS+ melanoma stem cells in metastatic neoplastic progression; and (3) Develop novel melanoma stem cell-targeted therapies. Thus, the proposal is highly relevant to efforts directed at developing novel therapeutic strategies to cancer therapy based on selectively targeting vital molecular pathways in cancer stem cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
-
批准号:10707346
-
项目类别:
-
资助金额:$223.18万
-
财政年份:2022
-
负责人:Markus H. Frank
-
依托单位:
Multicomponent Therapy for Age-related Skin Stem Cell Deficiency
-
批准号:10494654
-
项目类别:
-
资助金额:$235.16万
-
财政年份:2022
-
负责人:Markus H. Frank
-
依托单位:
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration
-
批准号:10494660
-
项目类别:
-
资助金额:$58.0万
-
财政年份:2022
-
负责人:Markus H. Frank
-
依托单位:
Stem Cell Integral Membrane Transporter ABCB5 and Dermal Regeneration
-
批准号:10707397
-
项目类别:
-
资助金额:$53.9万
-
财政年份:2022
-
负责人:Markus H. Frank
-
依托单位:
Immunology of human malignant melanoma initiating cells
-
批准号:8532856
-
项目类别:
-
资助金额:$37.71万
-
财政年份:2012
-
负责人:Markus H. Frank
-
依托单位:
Immunology of human malignant melanoma initiating cells
-
批准号:8239174
-
项目类别:
-
资助金额:$40.11万
-
财政年份:2012
-
负责人:Markus H. Frank
-
依托单位:
Immunology of human malignant melanoma initiating cells
-
批准号:8685190
-
项目类别:
-
资助金额:$35.32万
-
财政年份:2012
-
负责人:Markus H. Frank
-
依托单位:
Immunology of human malignant melanoma initiating cells
-
批准号:9112874
-
项目类别:
-
资助金额:$36.41万
-
财政年份:2012
-
负责人:Markus H. Frank
-
依托单位:
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression
-
批准号:8307737
-
项目类别:
-
资助金额:$33.66万
-
财政年份:2008
-
负责人:Markus H. Frank
-
依托单位:
Melanoma Stem Cells, Vasculogenesis and Neoplastic Progression
-
批准号:7692241
-
项目类别:
-
资助金额:$32.76万
-
财政年份:2008
-
负责人:Markus H. Frank
-
依托单位:
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
-
批准号:7221226
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:Markus H. Frank
-
依托单位:
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
-
批准号:7034755
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2006
-
负责人:Markus H. Frank
-
依托单位:
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
-
批准号:7763930
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:Markus H. Frank
-
依托单位:
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
-
批准号:7576195
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:Markus H. Frank
-
依托单位:
ABCB5 P-Glycoprotein in Cancer Multidrug Resistance
-
批准号:7362437
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:Markus H. Frank
-
依托单位:
P-glycoprotein Function in Allograft Rejection
-
批准号:6422411
-
项目类别:
-
资助金额:$12.85万
-
财政年份:2002
-
负责人:Markus H. Frank
-
依托单位:
P-glycoprotein Function in Allograft Rejection
-
批准号:6722805
-
项目类别:
-
资助金额:$12.85万
-
财政年份:2002
-
负责人:Markus H. Frank
-
依托单位:
P-glycoprotein Function in Allograft Rejection
-
批准号:6620842
-
项目类别:
-
资助金额:$12.85万
-
财政年份:2002
-
负责人:Markus H. Frank
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: